期刊文献+

苯甲酰胺衍生物对Hh信号通路抑制的理论研究 被引量:6

Theoretical study on the inhibition activity of 4-( Pyrimidin-2-ylamino) benzamide derivatives to hedgehog signaling pathway
下载PDF
导出
摘要 基于拓扑方法计算了16种嘧啶吗啉苯甲酰胺衍生物的电性距离矢量(Mt)。通过最佳变量子集回归建立其对Hedgehog信号通路抑制活性(IC50)与Mt的最佳三元数学模型(QSAR),其判定系数(R2)及逐一剔除法的交叉验证相关系数(Rcv2)分别为0.832、0.600。经Rcv2、VIF、FIT、AIC等检验,该模型具有良好的稳健性及预测能力。根据进入此模型的M66,M18,M2可知,影响嘧啶吗啉苯甲酰胺衍生物对Hedgehog信号通路抑制活性的主要因素是分子的二维结构特征CH3-、-CHf-、-NHg-、>N-和HO-等结构碎片。 The electronegativity distance vector( Mt) of 16 pyrimidin-morpholine benzamide derivatives were calculated by topological method. The quantitative structure-activity relationships( QSAR) was established by using leaps-and-bounds regression analysis for the inhibition activity( IC50) of above compounds to hedgehog signaling pathway along with the Mt. The traditional correlation coefficient( R2) and the cross-validation correlation coefficient( Rcv2) of leave-one-out( LOO) are 0. 832 and 0. 600,respectively. The QSAR models have both favorable estimation stability and good prediction capability by Rcv2,VIF,FIT,AICtests. M66,M18,M2 in the model shows that the main factor to affect the inhibition activity of pyrimidin-morpholine benzamide derivatives is a two-dimensional structural characteristics of the molecular CH3-,- CHf-,- NHg-, N- and HO- structure fragments.
出处 《化学研究与应用》 CAS CSCD 北大核心 2015年第4期483-488,共6页 Chemical Research and Application
基金 国家自然科学基金项目(21075138)资助 环境模拟与污染控制国家重点联合实验室开放基金项目(13K02ESPCT)资助 徐州市科技局基金项目(XM13B111)资助
关键词 嘧啶吗啉苯甲酰胺衍生物 HEDGEHOG信号通路 抑制活性 电性距离矢量 构效关系 pyrimidin-morpholine benzamide derivative hedgehog signaling pathway inhibition activity electronegativity distance vector quantitative structure-activity relationship
  • 相关文献

参考文献6

二级参考文献94

  • 1范英芳,郑艳莉,史智英.喹啉环取代喜树碱抗癌活性的定量构效关系研究[J].山西大学学报(自然科学版),2012,35(2):346-354. 被引量:1
  • 2丁伟,刘先军,于涛,吴文祥,刘娜,张艳秋.直链烷烃取代衍生物Wiener指数的简便计算方法[J].物理化学学报,2004,20(11):1369-1371. 被引量:5
  • 3Garcia-Echeverria C. Recent advances in the identification and development of 20S proteasome inhibitors [ J ]. Mini- Rev Med Chem,2002,2( 3 ) :247-259.
  • 4Groll M, Huber R, Moroder L. The persisting challenge ofselective and specific proteasome inhibition [ J ]. J Pept Sci,2009,15(2) :58-66.
  • 5MyungJ, Kim K B, Crews C M. The ubiquitin-proteasome pathway and proteasome inhibitors[ J]. Medicinal ResearchReviews ,2001.21 (4) :245-273.
  • 6deBettignies G, Coux O. Proteasome inhibitors: dozens of molecules and still counting [ J ]. Bioehimie, 2010, 92 ( 11 ) : 1530-1545.
  • 7Hines J, GroU M, Fahnestoek M, et al. Preteasome inhibi- tion by fellutamide B induces nerve growth factor synthesis [J]. Chem B/o/,2008,15(5) :501-512.
  • 8Lin G,Li D Y,Tamutenda C,et al. Fellutamide B is a po- tent inhibitor of the Mycobacterium tuberculosis protea- some[J]. Arch Biochem Biophys,2010,501 (2):214-220.
  • 9Lawrence H R,Aslamuzzaman K,Yunting L,et al. Synthe- sis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors [ J ]. Bioorg Med Chem, 20i0,18 (15) :5576-5592.
  • 10Momose I, Umezawa Y, Hirosawa S, et al. Structure-based design of derivatives of tyropeptin A as the potent and se- lective inhibitors of mammalian 20S proteasome [ J ]. Bioor g Med Chem Lett ,2005 ,15 ( 7 ) :1867-1871.

共引文献30

同被引文献43

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部